Marshall Posner, MD, on the Promise of Personalized mRNA Vaccines in Solid Malignancies


Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

Marshall Posner, MD, professor of medicine, director of head and neck medical oncology, and associate director of the Center for Personalized Cancer Therapeutics, Icahn School of Medicine at Mount Sinai, spoke with CancerNetworkÒ at the 2021 European Society of Medical Oncology Congress about exciting future innovations in oncology, including the prospect of personalized mRNA vaccines for various solid tumors. Although promising data have read out on this modality, Posner addresses hurdles that need to be overcome before the treatment can roll out.


There were some very interesting abstracts on precision vaccines, [which are] based on individual patient tumor targets. There are some very interesting data coming out on the ability to create these [vaccines]. I think the ability to create a vaccine that's mRNA based is really going to accelerate the ability to make individualized vaccines for various tumors. Once again, the problem will be the same. What else do you need besides the vaccine and the checkpoint blockade inhibitor, which is what people are generally using, to produce a robust immune response?

Related Videos
An AI-based system may reduce the time needed to match patients with cancer to suitable clinical trials.
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.